Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 15 entries
Sorted by: Best Match Show Resources per page
Fibroblast growth factors 19 and 21 in acute liver damage.

Annals of translational medicine

Shan Z, Alvarez-Sola G, Uriarte I, Arechederra M, Fernández-Barrena MG, Berasain C, Ju C, Avila MA.
PMID: 30069459
Ann Transl Med. 2018 Jun;6(12):257. doi: 10.21037/atm.2018.05.26.

Currently there are very few pharmacological options available to treat acute liver injury. Because its natural exposure to noxious stimuli the liver has developed a strong endogenous hepatoprotective capacity. Indeed, experimental evidence exposed a variety of endogenous hepatic and...

Cite
Shan Z, Alvarez-Sola G, Uriarte I, et al. Fibroblast growth factors 19 and 21 in acute liver damage. Ann Transl Med. 2018;6(12):257doi: 10.21037/atm.2018.05.26.
Shan, Z., Alvarez-Sola, G., Uriarte, I., Arechederra, M., Fernández-Barrena, M. G., Berasain, C., Ju, C., & Avila, M. A. (2018). Fibroblast growth factors 19 and 21 in acute liver damage. Annals of translational medicine, 6(12), 257. https://doi.org/10.21037/atm.2018.05.26
Shan, Zhao, et al. "Fibroblast growth factors 19 and 21 in acute liver damage." Annals of translational medicine vol. 6,12 (2018): 257. doi: https://doi.org/10.21037/atm.2018.05.26
Shan Z, Alvarez-Sola G, Uriarte I, Arechederra M, Fernández-Barrena MG, Berasain C, Ju C, Avila MA. Fibroblast growth factors 19 and 21 in acute liver damage. Ann Transl Med. 2018 Jun;6(12):257. doi: 10.21037/atm.2018.05.26. PMID: 30069459; PMCID: PMC6046301.
Copy Download .nbib Format: NLM
FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted.

Journal of hepatology

Vallejo A, Erice O, Entrialgo-Cadierno R, Feliu I, Guruceaga E, Perugorria MJ, Olaizola P, Muggli A, Macaya I, O'Dell M, Ruiz-Fernandez de Cordoba B, Ortiz-Espinosa S, Hezel AF, Arozarena I, Lecanda F, Avila MA, Fernandez-Barrena MG, Evert M, Ponz-Sarvise M, Calvisi DF, Banales JM, Vicent S, Bourgois P.
PMID: 33887357
J Hepatol. 2021 Aug;75(2):363-376. doi: 10.1016/j.jhep.2021.03.028. Epub 2021 Apr 20.

BACKGROUND & AIMS: Cholangiocarcinoma (CCA) is a neoplasia of the biliary tract driven by genetic, epigenetic and transcriptional mechanisms. Herein, we investigated the role of the transcription factor FOSL1, as well as its downstream transcriptional effectors, in the development...

Cite
Vallejo A, Erice O, Entrialgo-Cadierno R, et al. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. J Hepatol. 2021;75(2):363-376doi: 10.1016/j.jhep.2021.03.028.
Vallejo, A., Erice, O., Entrialgo-Cadierno, R., Feliu, I., Guruceaga, E., Perugorria, M. J., Olaizola, P., Muggli, A., Macaya, I., O'Dell, M., Ruiz-Fernandez de Cordoba, B., Ortiz-Espinosa, S., Hezel, A. F., Arozarena, I., Lecanda, F., Avila, M. A., Fernandez-Barrena, M. G., Evert, M., Ponz-Sarvise, M., Calvisi, D. F., Banales, J. M., Vicent, S., & Bourgois, P. (2021). FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. Journal of hepatology, 75(2), 363-376. https://doi.org/10.1016/j.jhep.2021.03.028
Vallejo, Adrián, et al. "FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted." Journal of hepatology vol. 75,2 (2021): 363-376. doi: https://doi.org/10.1016/j.jhep.2021.03.028
Vallejo A, Erice O, Entrialgo-Cadierno R, Feliu I, Guruceaga E, Perugorria MJ, Olaizola P, Muggli A, Macaya I, O'Dell M, Ruiz-Fernandez de Cordoba B, Ortiz-Espinosa S, Hezel AF, Arozarena I, Lecanda F, Avila MA, Fernandez-Barrena MG, Evert M, Ponz-Sarvise M, Calvisi DF, Banales JM, Vicent S, Bourgois P. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. J Hepatol. 2021 Aug;75(2):363-376. doi: 10.1016/j.jhep.2021.03.028. Epub 2021 Apr 20. PMID: 33887357.
Copy Download .nbib Format: NLM
Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma.

Hepatology (Baltimore, Md.)

Colyn L, Bárcena-Varela M, Álvarez-Sola G, Latasa MU, Uriarte I, Santamaría E, Herranz JM, Santos-Laso A, Arechederra M, Ruiz de Gauna M, Aspichueta P, Canale M, Casadei-Gardini A, Francesconi M, Carotti S, Morini S, Nelson LJ, Iraburu MJ, Chen C, Sangro B, Marin JJG, Martinez-Chantar ML, Banales JM, Arnes-Benito R, Huch M, Patino JM, Dar AA, Nosrati M, Oyarzábal J, Prósper F, Urman J, Cubero FJ, Trautwein C, Berasain C, Fernandez-Barrena MG, Avila MA.
PMID: 33222246
Hepatology. 2021 Jun;73(6):2380-2396. doi: 10.1002/hep.31642.

BACKGROUND AND AIMS: Cholangiocarcinoma (CCA) is a devastating disease often detected at advanced stages when surgery cannot be performed. Conventional and targeted systemic therapies perform poorly, and therefore effective drugs are urgently needed. Different epigenetic modifications occur in CCA...

Cite
Colyn L, Bárcena-Varela M, Álvarez-Sola G, et al. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma. Hepatology. 2021;73(6):2380-2396doi: 10.1002/hep.31642.
Colyn, L., Bárcena-Varela, M., Álvarez-Sola, G., Latasa, M. U., Uriarte, I., Santamaría, E., Herranz, J. M., Santos-Laso, A., Arechederra, M., Ruiz de Gauna, M., Aspichueta, P., Canale, M., Casadei-Gardini, A., Francesconi, M., Carotti, S., Morini, S., Nelson, L. J., Iraburu, M. J., Chen, C., Sangro, B., Marin, J. J. G., Martinez-Chantar, M. L., Banales, J. M., Arnes-Benito, R., Huch, M., Patino, J. M., Dar, A. A., Nosrati, M., Oyarzábal, J., Prósper, F., Urman, J., Cubero, F. J., Trautwein, C., Berasain, C., Fernandez-Barrena, M. G., & Avila, M. A. (2021). Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma. Hepatology (Baltimore, Md.), 73(6), 2380-2396. https://doi.org/10.1002/hep.31642
Colyn, Leticia, et al. "Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma." Hepatology (Baltimore, Md.) vol. 73,6 (2021): 2380-2396. doi: https://doi.org/10.1002/hep.31642
Colyn L, Bárcena-Varela M, Álvarez-Sola G, Latasa MU, Uriarte I, Santamaría E, Herranz JM, Santos-Laso A, Arechederra M, Ruiz de Gauna M, Aspichueta P, Canale M, Casadei-Gardini A, Francesconi M, Carotti S, Morini S, Nelson LJ, Iraburu MJ, Chen C, Sangro B, Marin JJG, Martinez-Chantar ML, Banales JM, Arnes-Benito R, Huch M, Patino JM, Dar AA, Nosrati M, Oyarzábal J, Prósper F, Urman J, Cubero FJ, Trautwein C, Berasain C, Fernandez-Barrena MG, Avila MA. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma. Hepatology. 2021 Jun;73(6):2380-2396. doi: 10.1002/hep.31642. PMID: 33222246.
Copy Download .nbib Format: NLM
Splicing Factor SLU7 Prevents Oxidative Stress-Mediated Hepatocyte Nuclear Factor 4α Degradation, Preserving Hepatic Differentiation and Protecting From Liver Damage.

Hepatology (Baltimore, Md.)

Gárate-Rascón M, Recalde M, Jimenez M, Elizalde M, Azkona M, Uriarte I, Latasa MU, Urtasun R, Bilbao I, Sangro B, Garcia-Ruiz C, Fernandez-Checa JC, Corrales FJ, Esquivel A, Pineda-Lucena A, Fernández-Barrena MG, Ávila MA, Arechederra M, Berasain C.
PMID: 34170569
Hepatology. 2021 Nov;74(5):2791-2807. doi: 10.1002/hep.32029. Epub 2021 Sep 25.

BACKGROUND AND AIMS: Hepatocellular dedifferentiation is emerging as an important determinant in liver disease progression. Preservation of mature hepatocyte identity relies on a set of key genes, predominantly the transcription factor hepatocyte nuclear factor 4α (HNF4α) but also splicing...

Cite
Gárate-Rascón M, Recalde M, Jimenez M, et al. Splicing Factor SLU7 Prevents Oxidative Stress-Mediated Hepatocyte Nuclear Factor 4α Degradation, Preserving Hepatic Differentiation and Protecting From Liver Damage. Hepatology. 2021;74(5):2791-2807doi: 10.1002/hep.32029.
Gárate-Rascón, M., Recalde, M., Jimenez, M., Elizalde, M., Azkona, M., Uriarte, I., Latasa, M. U., Urtasun, R., Bilbao, I., Sangro, B., Garcia-Ruiz, C., Fernandez-Checa, J. C., Corrales, F. J., Esquivel, A., Pineda-Lucena, A., Fernández-Barrena, M. G., Ávila, M. A., Arechederra, M., & Berasain, C. (2021). Splicing Factor SLU7 Prevents Oxidative Stress-Mediated Hepatocyte Nuclear Factor 4α Degradation, Preserving Hepatic Differentiation and Protecting From Liver Damage. Hepatology (Baltimore, Md.), 74(5), 2791-2807. https://doi.org/10.1002/hep.32029
Gárate-Rascón, María, et al. "Splicing Factor SLU7 Prevents Oxidative Stress-Mediated Hepatocyte Nuclear Factor 4α Degradation, Preserving Hepatic Differentiation and Protecting From Liver Damage." Hepatology (Baltimore, Md.) vol. 74,5 (2021): 2791-2807. doi: https://doi.org/10.1002/hep.32029
Gárate-Rascón M, Recalde M, Jimenez M, Elizalde M, Azkona M, Uriarte I, Latasa MU, Urtasun R, Bilbao I, Sangro B, Garcia-Ruiz C, Fernandez-Checa JC, Corrales FJ, Esquivel A, Pineda-Lucena A, Fernández-Barrena MG, Ávila MA, Arechederra M, Berasain C. Splicing Factor SLU7 Prevents Oxidative Stress-Mediated Hepatocyte Nuclear Factor 4α Degradation, Preserving Hepatic Differentiation and Protecting From Liver Damage. Hepatology. 2021 Nov;74(5):2791-2807. doi: 10.1002/hep.32029. Epub 2021 Sep 25. PMID: 34170569.
Copy Download .nbib Format: NLM
Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge.

Oncogene

Carotti S, Zingariello M, Francesconi M, D'Andrea L, Latasa MU, Colyn L, Fernandez-Barrena MG, Flammia RS, Falchi M, Righi D, Pedini G, Pantano F, Bagni C, Perrone G, Rana RA, Avila MA, Morini S, Zalfa F.
PMID: 34017076
Oncogene. 2021 Jun;40(23):4033-4049. doi: 10.1038/s41388-021-01824-3. Epub 2021 May 20.

Intrahepatic cholangiocarcinoma (iCCA) is a rare malignancy of the intrahepatic biliary tract with a very poor prognosis. Although some clinicopathological parameters can be prognostic factors for iCCA, the molecular prognostic markers and potential mechanisms of iCCA have not been...

Cite
Carotti S, Zingariello M, Francesconi M, et al. Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge. Oncogene. 2021;40(23):4033-4049doi: 10.1038/s41388-021-01824-3.
Carotti, S., Zingariello, M., Francesconi, M., D'Andrea, L., Latasa, M. U., Colyn, L., Fernandez-Barrena, M. G., Flammia, R. S., Falchi, M., Righi, D., Pedini, G., Pantano, F., Bagni, C., Perrone, G., Rana, R. A., Avila, M. A., Morini, S., & Zalfa, F. (2021). Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge. Oncogene, 40(23), 4033-4049. https://doi.org/10.1038/s41388-021-01824-3
Carotti, Simone, et al. "Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge." Oncogene vol. 40,23 (2021): 4033-4049. doi: https://doi.org/10.1038/s41388-021-01824-3
Carotti S, Zingariello M, Francesconi M, D'Andrea L, Latasa MU, Colyn L, Fernandez-Barrena MG, Flammia RS, Falchi M, Righi D, Pedini G, Pantano F, Bagni C, Perrone G, Rana RA, Avila MA, Morini S, Zalfa F. Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge. Oncogene. 2021 Jun;40(23):4033-4049. doi: 10.1038/s41388-021-01824-3. Epub 2021 May 20. PMID: 34017076; PMCID: PMC8195741.
Copy Download .nbib Format: NLM
The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?.

Cancers

Gonzalez-Sanchez E, Vaquero J, Férnandez-Barrena MG, Lasarte JJ, Avila MA, Sarobe P, Reig M, Calvo M, Fabregat I.
PMID: 34209646
Cancers (Basel). 2021 Jun 29;13(13). doi: 10.3390/cancers13133248.

Transforming Growth Factor-beta (TGF-β) superfamily members are essential for tissue homeostasis and consequently, dysregulation of their signaling pathways contributes to the development of human diseases. In the liver, TGF-β signaling participates in all the stages of disease progression from...

Cite
Gonzalez-Sanchez E, Vaquero J, Férnandez-Barrena MG, et al. The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?. Cancers (Basel). 2021;13(13)doi: 10.3390/cancers13133248.
Gonzalez-Sanchez, E., Vaquero, J., Férnandez-Barrena, M. G., Lasarte, J. J., Avila, M. A., Sarobe, P., Reig, M., Calvo, M., & Fabregat, I. (2021). The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?. Cancers, 13(13), . https://doi.org/10.3390/cancers13133248
Gonzalez-Sanchez, Ester, et al. "The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?." Cancers vol. 13,13 (2021). doi: https://doi.org/10.3390/cancers13133248
Gonzalez-Sanchez E, Vaquero J, Férnandez-Barrena MG, Lasarte JJ, Avila MA, Sarobe P, Reig M, Calvo M, Fabregat I. The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?. Cancers (Basel). 2021 Jun 29;13(13). doi: 10.3390/cancers13133248. PMID: 34209646; PMCID: PMC8268320.
Copy Download .nbib Format: NLM
Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis.

Cancers

Claveria-Cabello A, Colyn L, Uriarte I, Latasa MU, Arechederra M, Herranz JM, Alvarez L, Urman JM, Martinez-Chantar ML, Banales JM, Sangro B, Rombouts K, Oyarzabal J, Marin JJG, Berasain C, Avila MA, Fernandez-Barrena MG.
PMID: 33322158
Cancers (Basel). 2020 Dec 13;12(12). doi: 10.3390/cancers12123748.

Liver fibrosis, a common hallmark of chronic liver disease (CLD), is characterized by the accumulation of extracellular matrix secreted by activated hepatic fibroblasts and stellate cells (HSC). Fibrogenesis involves multiple cellular and molecular processes and is intimately linked to...

Cite
Claveria-Cabello A, Colyn L, Uriarte I, et al. Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. Cancers (Basel). 2020;12(12)doi: 10.3390/cancers12123748.
Claveria-Cabello, A., Colyn, L., Uriarte, I., Latasa, M. U., Arechederra, M., Herranz, J. M., Alvarez, L., Urman, J. M., Martinez-Chantar, M. L., Banales, J. M., Sangro, B., Rombouts, K., Oyarzabal, J., Marin, J. J. G., Berasain, C., Avila, M. A., & Fernandez-Barrena, M. G. (2020). Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. Cancers, 12(12), . https://doi.org/10.3390/cancers12123748
Claveria-Cabello, Alex, et al. "Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis." Cancers vol. 12,12 (2020). doi: https://doi.org/10.3390/cancers12123748
Claveria-Cabello A, Colyn L, Uriarte I, Latasa MU, Arechederra M, Herranz JM, Alvarez L, Urman JM, Martinez-Chantar ML, Banales JM, Sangro B, Rombouts K, Oyarzabal J, Marin JJG, Berasain C, Avila MA, Fernandez-Barrena MG. Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. Cancers (Basel). 2020 Dec 13;12(12). doi: 10.3390/cancers12123748. PMID: 33322158; PMCID: PMC7763137.
Copy Download .nbib Format: NLM
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg.

JHEP reports : innovation in hepatology

Fernández-Barrena MG, Arechederra M, Colyn L, Berasain C, Avila MA.
PMID: 33134907
JHEP Rep. 2020 Aug 07;2(6):100167. doi: 10.1016/j.jhepr.2020.100167. eCollection 2020 Dec.

Hepatocellular carcinoma (HCC) is a deadly tumour whose causative agents are generally well known, but whose pathogenesis remains poorly understood. Nevertheless, key genetic alterations are emerging from a heterogeneous molecular landscape, providing information on the tumorigenic process from initiation...

Cite
Fernández-Barrena MG, Arechederra M, Colyn L, et al. Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg. JHEP Rep. 2020;2(6):100167doi: 10.1016/j.jhepr.2020.100167.
Fernández-Barrena, M. G., Arechederra, M., Colyn, L., Berasain, C., & Avila, M. A. (2020). Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg. JHEP reports : innovation in hepatology, 2(6), 100167. https://doi.org/10.1016/j.jhepr.2020.100167
Fernández-Barrena, Maite G, et al. "Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg." JHEP reports : innovation in hepatology vol. 2,6 (2020): 100167. doi: https://doi.org/10.1016/j.jhepr.2020.100167
Fernández-Barrena MG, Arechederra M, Colyn L, Berasain C, Avila MA. Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg. JHEP Rep. 2020 Aug 07;2(6):100167. doi: 10.1016/j.jhepr.2020.100167. eCollection 2020 Dec. PMID: 33134907; PMCID: PMC7585149.
Copy Download .nbib Format: NLM
Splicing Factor SLU7 Prevents Oxidative Stress-Mediated Hepatocyte Nuclear Factor 4α Degradation, Preserving Hepatic Differentiation and Protecting From Liver Damage.

Hepatology (Baltimore, Md.)

Gárate-Rascón M, Recalde M, Jimenez M, Elizalde M, Azkona M, Uriarte I, Latasa MU, Urtasun R, Bilbao I, Sangro B, Garcia-Ruiz C, Fernandez-Checa JC, Corrales FJ, Esquivel A, Pineda-Lucena A, Fernández-Barrena MG, Ávila MA, Arechederra M, Berasain C, O'Cathain A, Croot L.
PMID: 34170569
Hepatology. 2021 Nov;74(5):2791-2807. doi: 10.1002/hep.32029. Epub 2021 Sep 25.

BACKGROUND AND AIMS: Hepatocellular dedifferentiation is emerging as an important determinant in liver disease progression. Preservation of mature hepatocyte identity relies on a set of key genes, predominantly the transcription factor hepatocyte nuclear factor 4α (HNF4α) but also splicing...

Cite
Gárate-Rascón M, Recalde M, Jimenez M, et al. Splicing Factor SLU7 Prevents Oxidative Stress-Mediated Hepatocyte Nuclear Factor 4α Degradation, Preserving Hepatic Differentiation and Protecting From Liver Damage. Hepatology. 2021;74(5):2791-2807doi: 10.1002/hep.32029.
Gárate-Rascón, M., Recalde, M., Jimenez, M., Elizalde, M., Azkona, M., Uriarte, I., Latasa, M. U., Urtasun, R., Bilbao, I., Sangro, B., Garcia-Ruiz, C., Fernandez-Checa, J. C., Corrales, F. J., Esquivel, A., Pineda-Lucena, A., Fernández-Barrena, M. G., Ávila, M. A., Arechederra, M., Berasain, C., O'Cathain, A., & Croot, L. (2021). Splicing Factor SLU7 Prevents Oxidative Stress-Mediated Hepatocyte Nuclear Factor 4α Degradation, Preserving Hepatic Differentiation and Protecting From Liver Damage. Hepatology (Baltimore, Md.), 74(5), 2791-2807. https://doi.org/10.1002/hep.32029
Gárate-Rascón, María, et al. "Splicing Factor SLU7 Prevents Oxidative Stress-Mediated Hepatocyte Nuclear Factor 4α Degradation, Preserving Hepatic Differentiation and Protecting From Liver Damage." Hepatology (Baltimore, Md.) vol. 74,5 (2021): 2791-2807. doi: https://doi.org/10.1002/hep.32029
Gárate-Rascón M, Recalde M, Jimenez M, Elizalde M, Azkona M, Uriarte I, Latasa MU, Urtasun R, Bilbao I, Sangro B, Garcia-Ruiz C, Fernandez-Checa JC, Corrales FJ, Esquivel A, Pineda-Lucena A, Fernández-Barrena MG, Ávila MA, Arechederra M, Berasain C, O'Cathain A, Croot L. Splicing Factor SLU7 Prevents Oxidative Stress-Mediated Hepatocyte Nuclear Factor 4α Degradation, Preserving Hepatic Differentiation and Protecting From Liver Damage. Hepatology. 2021 Nov;74(5):2791-2807. doi: 10.1002/hep.32029. Epub 2021 Sep 25. PMID: 34170569.
Copy Download .nbib Format: NLM
Activation of the Unfolded Protein Response (UPR) Is Associated with Cholangiocellular Injury, Fibrosis and Carcinogenesis in an Experimental Model of Fibropolycystic Liver Disease.

Cancers

Chen C, Wu H, Ye H, Tortajada A, Rodríguez-Perales S, Torres-Ruiz R, Vidal A, Peligros MI, Reissing J, Bruns T, Mohamed MR, Zheng K, Lujambio A, Iraburu MJ, Colyn L, Latasa MU, Arechederra M, Fernández-Barrena MG, Berasain C, Vaquero J, Bañares R, Nelson LJ, Trautwein C, Davis RJ, Martinez-Naves E, Nevzorova YA, Villanueva A, Avila MA, Cubero FJ.
PMID: 35008241
Cancers (Basel). 2021 Dec 24;14(1). doi: 10.3390/cancers14010078.

Fibropolycystic liver disease is characterized by hyperproliferation of the biliary epithelium and the formation of multiple dilated cysts, a process associated with unfolded protein response (UPR). In the present study, we aimed to understand the mechanisms of cyst formation...

Cite
Chen C, Wu H, Ye H, et al. Activation of the Unfolded Protein Response (UPR) Is Associated with Cholangiocellular Injury, Fibrosis and Carcinogenesis in an Experimental Model of Fibropolycystic Liver Disease. Cancers (Basel). 2021;14(1)doi: 10.3390/cancers14010078.
Chen, C., Wu, H., Ye, H., Tortajada, A., Rodríguez-Perales, S., Torres-Ruiz, R., Vidal, A., Peligros, M. I., Reissing, J., Bruns, T., Mohamed, M. R., Zheng, K., Lujambio, A., Iraburu, M. J., Colyn, L., Latasa, M. U., Arechederra, M., Fernández-Barrena, M. G., Berasain, C., Vaquero, J., Bañares, R., Nelson, L. J., Trautwein, C., Davis, R. J., Martinez-Naves, E., Nevzorova, Y. A., Villanueva, A., Avila, M. A., & Cubero, F. J. (2021). Activation of the Unfolded Protein Response (UPR) Is Associated with Cholangiocellular Injury, Fibrosis and Carcinogenesis in an Experimental Model of Fibropolycystic Liver Disease. Cancers, 14(1), . https://doi.org/10.3390/cancers14010078
Chen, Chaobo, et al. "Activation of the Unfolded Protein Response (UPR) Is Associated with Cholangiocellular Injury, Fibrosis and Carcinogenesis in an Experimental Model of Fibropolycystic Liver Disease." Cancers vol. 14,1 (2021). doi: https://doi.org/10.3390/cancers14010078
Chen C, Wu H, Ye H, Tortajada A, Rodríguez-Perales S, Torres-Ruiz R, Vidal A, Peligros MI, Reissing J, Bruns T, Mohamed MR, Zheng K, Lujambio A, Iraburu MJ, Colyn L, Latasa MU, Arechederra M, Fernández-Barrena MG, Berasain C, Vaquero J, Bañares R, Nelson LJ, Trautwein C, Davis RJ, Martinez-Naves E, Nevzorova YA, Villanueva A, Avila MA, Cubero FJ. Activation of the Unfolded Protein Response (UPR) Is Associated with Cholangiocellular Injury, Fibrosis and Carcinogenesis in an Experimental Model of Fibropolycystic Liver Disease. Cancers (Basel). 2021 Dec 24;14(1). doi: 10.3390/cancers14010078. PMID: 35008241; PMCID: PMC8750579.
Copy Download .nbib Format: NLM
Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma.

Hepatology (Baltimore, Md.)

Colyn L, Bárcena-Varela M, Álvarez-Sola G, Latasa MU, Uriarte I, Santamaría E, Herranz JM, Santos-Laso A, Arechederra M, Ruiz de Gauna M, Aspichueta P, Canale M, Casadei-Gardini A, Francesconi M, Carotti S, Morini S, Nelson LJ, Iraburu MJ, Chen C, Sangro B, Marin JJG, Martinez-Chantar ML, Banales JM, Arnes-Benito R, Huch M, Patino JM, Dar AA, Nosrati M, Oyarzábal J, Prósper F, Urman J, Cubero FJ, Trautwein C, Berasain C, Fernandez-Barrena MG, Avila MA.
PMID: 33222246
Hepatology. 2021 Jun;73(6):2380-2396. doi: 10.1002/hep.31642.

BACKGROUND AND AIMS: Cholangiocarcinoma (CCA) is a devastating disease often detected at advanced stages when surgery cannot be performed. Conventional and targeted systemic therapies perform poorly, and therefore effective drugs are urgently needed. Different epigenetic modifications occur in CCA...

Cite
Colyn L, Bárcena-Varela M, Álvarez-Sola G, et al. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma. Hepatology. 2021;73(6):2380-2396doi: 10.1002/hep.31642.
Colyn, L., Bárcena-Varela, M., Álvarez-Sola, G., Latasa, M. U., Uriarte, I., Santamaría, E., Herranz, J. M., Santos-Laso, A., Arechederra, M., Ruiz de Gauna, M., Aspichueta, P., Canale, M., Casadei-Gardini, A., Francesconi, M., Carotti, S., Morini, S., Nelson, L. J., Iraburu, M. J., Chen, C., Sangro, B., Marin, J. J. G., Martinez-Chantar, M. L., Banales, J. M., Arnes-Benito, R., Huch, M., Patino, J. M., Dar, A. A., Nosrati, M., Oyarzábal, J., Prósper, F., Urman, J., Cubero, F. J., Trautwein, C., Berasain, C., Fernandez-Barrena, M. G., & Avila, M. A. (2021). Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma. Hepatology (Baltimore, Md.), 73(6), 2380-2396. https://doi.org/10.1002/hep.31642
Colyn, Leticia, et al. "Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma." Hepatology (Baltimore, Md.) vol. 73,6 (2021): 2380-2396. doi: https://doi.org/10.1002/hep.31642
Colyn L, Bárcena-Varela M, Álvarez-Sola G, Latasa MU, Uriarte I, Santamaría E, Herranz JM, Santos-Laso A, Arechederra M, Ruiz de Gauna M, Aspichueta P, Canale M, Casadei-Gardini A, Francesconi M, Carotti S, Morini S, Nelson LJ, Iraburu MJ, Chen C, Sangro B, Marin JJG, Martinez-Chantar ML, Banales JM, Arnes-Benito R, Huch M, Patino JM, Dar AA, Nosrati M, Oyarzábal J, Prósper F, Urman J, Cubero FJ, Trautwein C, Berasain C, Fernandez-Barrena MG, Avila MA. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma. Hepatology. 2021 Jun;73(6):2380-2396. doi: 10.1002/hep.31642. PMID: 33222246.
Copy Download .nbib Format: NLM
Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach.

Cancers

Urman JM, Herranz JM, Uriarte I, Rullán M, Oyón D, González B, Fernandez-Urién I, Carrascosa J, Bolado F, Zabalza L, Arechederra M, Alvarez-Sola G, Colyn L, Latasa MU, Puchades-Carrasco L, Pineda-Lucena A, Iraburu MJ, Iruarrizaga-Lejarreta M, Alonso C, Sangro B, Purroy A, Gil I, Carmona L, Cubero FJ, Martínez-Chantar ML, Banales JM, Romero MR, Macias RIR, Monte MJ, Marín JJG, Vila JJ, Corrales FJ, Berasain C, Fernández-Barrena MG, Avila MA.
PMID: 32575903
Cancers (Basel). 2020 Jun 21;12(6). doi: 10.3390/cancers12061644.

Cholangiocarcinoma (CCA) and pancreatic adenocarcinoma (PDAC) may lead to the development of extrahepatic obstructive cholestasis. However, biliary stenoses can also be caused by benign conditions, and the identification of their etiology still remains a clinical challenge. We performed metabolomic...

Cite
Urman JM, Herranz JM, Uriarte I, et al. Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach. Cancers (Basel). 2020;12(6)doi: 10.3390/cancers12061644.
Urman, J. M., Herranz, J. M., Uriarte, I., Rullán, M., Oyón, D., González, B., Fernandez-Urién, I., Carrascosa, J., Bolado, F., Zabalza, L., Arechederra, M., Alvarez-Sola, G., Colyn, L., Latasa, M. U., Puchades-Carrasco, L., Pineda-Lucena, A., Iraburu, M. J., Iruarrizaga-Lejarreta, M., Alonso, C., Sangro, B., Purroy, A., Gil, I., Carmona, L., Cubero, F. J., Martínez-Chantar, M. L., Banales, J. M., Romero, M. R., Macias, R. I. R., Monte, M. J., Marín, J. J. G., Vila, J. J., Corrales, F. J., Berasain, C., Fernández-Barrena, M. G., & Avila, M. A. (2020). Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach. Cancers, 12(6), . https://doi.org/10.3390/cancers12061644
Urman, Jesús M, et al. "Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach." Cancers vol. 12,6 (2020). doi: https://doi.org/10.3390/cancers12061644
Urman JM, Herranz JM, Uriarte I, Rullán M, Oyón D, González B, Fernandez-Urién I, Carrascosa J, Bolado F, Zabalza L, Arechederra M, Alvarez-Sola G, Colyn L, Latasa MU, Puchades-Carrasco L, Pineda-Lucena A, Iraburu MJ, Iruarrizaga-Lejarreta M, Alonso C, Sangro B, Purroy A, Gil I, Carmona L, Cubero FJ, Martínez-Chantar ML, Banales JM, Romero MR, Macias RIR, Monte MJ, Marín JJG, Vila JJ, Corrales FJ, Berasain C, Fernández-Barrena MG, Avila MA. Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach. Cancers (Basel). 2020 Jun 21;12(6). doi: 10.3390/cancers12061644. PMID: 32575903; PMCID: PMC7352944.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 15 entries